Jiao Tai Wan Attenuates Hepatic Lipid Accumulation in Type 2 Diabetes Mellitus

Table 4

General characteristics and laboratory data of diabetic patients at baseline and 12 weeks after the therapy.

Group	Control		JTW
	Before	After	Before	After
Subjects (M/F)	9/11		9/11
Age (years)	46.1±7.3		46.2±6.1
BMI (kg/m^2)	24.9±3.5	24.7±3.3	25.1±3.6	22.9±2.9^#∗
WC (cm) (F)	83.4±5.7	83.3±6.5	82.9±5.8	80.6±4.2^#∗
WC (cm) (M)	90.6±7.0	90.5±8.1	91.7±6.7	89.1±5.6^#∗
WHR (F)	0.87±0.06	0.87±0.05	0.88±0.05	0.86±0.03^#∗
WHR (M)	0.94±0.07	0.93±0.07	0.94±0.04	0.91±0.05^#∗
SBP (mmHg)	132±22	130±24	130±20	130±20
DBP (mmHg)	80±12	79±10	80±10	79±12
FPG (mmol/L)	7.64 (6.20, 9.37)	7.67 (6.41, 9.25)	7.89 (6.10, 9.22)	6.78 (4.01, 8.69)#∗
2hPPG (mmol/L)	13.16±4.15	13.21±4.55	13.25±4.09	10.55±3.51^#∗
FINS (μIU/L)	7.59 (4.33, 10.42)	7.61 (4.57, 9.99)	7.52 (4.11, 12.92)	6.04 (4.20, 9.61)#∗
HbA1c (%)	7.81±1.61	7.80±1.59	7.84±1.33	6.91±1.48^#∗
TC (mmol/L)	4.76±0.73	4.82±0.88	4.94±0.83	3.89±0.63^#∗
TG (mmol/L)	1.32 (1.05, 2.38)	1.31 (1.01, 2.23)	1.29 (1.02, 2.75)	1.18 (0.94, 2.13)#∗
HDL-C (mmol/L)	1.24 (0.98, 1.58)	1.25 (1.03, 1.60)	1.27 (1.03, 1.90)	1.26 (0.96, 1.87)
LDL-C (mmol/L)	2.89±0.82	2.90±0.74	2.95±0.76	1.87±0.77^#∗
ALT (U/L)	26 (18, 35)	25 (17, 35)	21 (18, 40)	24 (17, 35)
AST (U/L)	22 (15, 31)	21 (16, 32)	19 (11, 35)	21 (10, 30)
HTC (%)	9.63 (5.87, 11.18)	10.79 (6.75, 19.99)#	9.81 (5.76, 15.09)	6.54 (4.82, 13.08)#∗

Normally distributed data are presented as the mean ± SD; nonnormally distributed data are presented as the median with the 25th and 75th percentiles in parenthesis. ^#𝑃<0.05 versus pretreatment. ^∗𝑃<0.05 versus the control group.